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Abstract
Purpose: The understanding of the role of genetic alterations in Wilms tumor development could
be greatly advanced using a genetically engineered mouse models that can replicate the
development and progression of this disease in human patients and can be monitored using
non-invasive structural and molecular imaging optimized for renal tumors.
Procedures: Repetitive dual-contrast computed tomography (CT; intravenous and intraperito-
neal contrast), T2-weighted magnetic resonance imaging (MRI), and delayed 2-deoxy-2-[18F]
fluoro-D-glucose (18F-FDG) positron emission tomography (PET) were utilized for characteriza-
tion of Igf2 biallelic expression/Wt1 knockout mouse model of Wilms tumor. For CT imaging,
Ioversol 678 mg/ml in 200 μl was administered i.p. followed by 100 μl injected intravenously at
20 and 15 min prior to imaging, respectively. Static PET imaging studies were acquired at 1, 2,
and 3 h after i.v. administration of 18F-FDG (400 μCi). Coronal and sagittal T1-weighted images
(TE/TR 8.5/620 ms) were acquired before and immediately after i.v. injection of 0.4 ml/kg
gadopentetate dimeglumine followed by T2-weighted images (TE/TR 60/300 ms). Tumor tissue
samples were characterized by histopathology and immunohistochemistry for Glut1, FASN,
Ki67, and CD34. In addition, six Wt1-Igf2 mice were treated with a mitogen-activated protein
kinase (MEK) inhibitor U0126 (50 μmol/kg i.p.) every 4 days for 6 weeks. 18F-FDG PET/CT
imaging was repeated at different days after initiation of therapy with U0126. The percent
change of initial tumor volume and SUV was compared to non-treated historic control animals.
Results: Overall, the best tumor-to-adjacent kidney contrast as well as soft tissue contrast for
other abdominal organs was achieved using T2-weighted MRI. Delayed 18F-FDG PET (3-h post
18F-FDG administration) and dual-contrast CT (intravenous and intraperitoneal contrast)
provided a more accurate anatomic and metabolic characterization of Wilms tumors in Wt1-
Igf2 mice during early development and progression of renal tumors. Over the 8-month period,
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46 Wt1-Igf2 mice and 8 littermate control mice were studied. Renal tumors were identified in
54.3 % of Wt1-Igf2 mice between post-natal 50–100 days. In 35.6 % of Wt1-Igf2 mice, tumors
were localized in the right kidney; in 24 %, in the left kidney, while 40.4 % of Wt1-Igf2 mice had
bilateral kidney tumors. Metastatic lesions were identified in 15.4 % of Wt1-Igf2 mice. Increased
levels of Glut1 and IGF1R expression, high Ki67 labeling index, and a dense network of CD34+
microvessels in renal tumors was consistent with increased 18F-FDG accumulation. Treatment
with a MEK 1/2 inhibitor U0126 did not cause the inhibition of tumor growth as compared to
untreated animals. However, after the first three to four doses (~2 weeks of treatment), a
decrease in 18F-FDG SUV was observed, as compared to pre-treatment levels (pG0.05, paired
Student t test), which constitutes a metabolic response. Six weeks later, despite continuing
therapy, the 18F-FDG SUV increased again to previous levels.
Conclusions: The optimized dual contrast PET/CT imaging with early post i.v. and i.p. contrast CT
and 3 h delayed PET imaging after 18F-FDG administration provides a sensitive and reliable method
for detecting early tumor lesions in this endogenousmousemodel of Wilms tumor and for monitoring
their growth in response to targeted therapies. Therapy with MEK inhibitor U0126 produces only a
transient inhibition of tumor glycolytic activity but does not inhibit tumor growth, which is due to
continuing IGF2-induced signaling from IGF1R through the PI3K-AKT-mTOR pathway.
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Introduction
Wilms tumor or nephroblastoma, an embryonal neo-plasm of the kidney is the second most common intra-
abdominal cancer in children and accounts for more than
95 % of all tumors of the kidney in the pediatric patients [1].
The pathogenesis of Wilms tumor is complex yet provides
insight into the relationship of embryology and oncogenesis.
The understanding of the role of genetic alterations in tumor
development has advanced slowly due to the need of a
suitable Wilms tumor mouse model. Recent technological
advances now allow manipulation of the mouse genome to
constitutively or conditionally alter the expression of crucial
genes leading to development of a particular tumor model.
The known mutations involved in Wilms tumor are
inactivation of WT1 due to germline and/or somatic
mutation, somatic stabilizing CTNN1B mutations, somatic
deletion of WTX, and somatic p53 mutation [2].
Subcutaneous (s.c.) tumor xenograft models of Wilms
tumor using SK-NEP-1 and G401 cell lines have been
employed extensively to assess the effectiveness of new
drugs and various treatment approaches [3–9]. These s.c.
Wilms tumor models result in highly reproducible data
because tumor growth can be visually monitored and easily
measured. However, s.c. tumor xenograft models do not
adequately replicate natural organotypic tumor stromal
microenvironment achieved by orthotopic xenograft models
of Wilms tumor [10], which, however, are not always
suitable to studies of the mechanisms of oncogenesis, tumor
maintenance, progression, and response to therapy [11, 12].
Furthermore, recent studies demonstrated that the SK-NEP-1
cell line, previously thought to represent anaplastic Wilms
tumor, is instead related to Ewing sarcoma [8] and that the
G401 cell line is actually a rhabdoid kidney tumor [9]. Thus,
the availability of adequate orthotopic xenograft models of
Wilms tumor is very limited.
In contrast, transgenic and knockout tumor models enable
studies on organ-speciﬁc oncogenesis, provide information on
how an isolated genetic alteration contributes to mechanisms of
malignant transformation and progression, and lay the ground
work for targeted therapies. However, due to the lack of visual
control and easy access for caliper-based measurements,
monitoring of tumor growth in both orthotopic and, especially,
endogenous tumor models requires repetitive non-invasive
anatomic and/or functional imaging [13].
Usually, for longitudinal characterization of orthotopic
and endogenous mouse models of renal tumors, mice are
euthanized at different time points after the initial implan-
tation of tumor cells or at different weeks after birth (in the
case of endogenous tumors) and kidneys are harvested for
tumor detection, measurements, and histopathology [14, 15].
Studies in orthotopic Wilms tumor models in mice relied on
palpation for monitoring tumor growth, which allowed for
detection of only large tumors (approximately 3 cm2,
5 weeks after cell injection) [3]. High frequency ultrasound
imaging (USI) allowed detection and morphologic charac-
terization of orthotopic Wilms tumor xenografts as less than
2 mm2 at 3–5 weeks after tumor cell implantation [16], but
the reproducibility of USI is low because it is operator-
dependent. Orthotopic xenografts of human renal carcinoma
cells transduced with ﬁreﬂy luciferase (FLuc) reporter gene
allowed for reliable, rapid, and noninvasive longitudinal
monitoring of tumor growth in vivo with bioluminescence
imaging (BLI) [17]. Because transgenic mouse models of
renal carcinomas expressing reporter genes for BLI have not
been developed yet, other approaches using non-invasive
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anatomic and/or molecular imaging should to be evaluated
for tumor detection and therapy monitoring. Furthermore,
BLI lacks the depth information and is not suitable for
determination of tumor size based on BLI signals.
Here, we describe an optimized imaging methodology
with dual contrast computed tomography (CT; intravenous
and intraperitoneal), T2-weighted magnetic resonance imag-
ing (MRI), and delayed 2-deoxy-2-[18F]ﬂuoro-D-glucose
(18F-FDG) positron emission tomography (PET) for charac-
terization of a recently developed Igf2 biallelic expression/
Wt1 knockout mouse model of Wilms tumor [18], which
allowed for more accurate repetitive anatomic and metabolic
imaging during the early development and progression of
Wilms tumors and their responses to experimental targeted
therapies. We demonstrate that Wt1 ablation and Igf2
upregulation in tumors results in up-regulation of glucose
utilization during initial stages of tumor development,
followed by a gradual decrease in tumor glycolytic activity,
consistent with the development of large areas of hemor-
rhagic necrosis. Furthermore, we demonstrate that therapy
with a mitogen-activated protein kinase (MEK) inhibitor
U0126 causes a transient decrease in tumor glycolytic
activity, consistent with downregulation of signal transduc-
tion downstream MEK, but does not signiﬁcantly affect the
rate of tumor growth.
Materials and Methods
Tumor Model
All studies involving animals were performed in accordance with
regulations of the Institutional Animal Care and Use Committee
(IACUC) at the UT MD Anderson Cancer Center. The new
endogenous Wilms tumor model was recently described [18]. Brieﬂy,
tumor-watch cohort (Wt1–/ﬂH19+/–mCre-ERTM) and littermate controls
(Wt1+/ﬂH19+/–mCre-ERTM, Wt1–/ﬂH19+/–m, and Wt1+/ﬂH19+/–m) were
generated by crossing Wt1ﬂ/ﬂH19–/– females with Wt1+/–Cre-ERTM
males. TheWt1ﬂ allele, upon induction of Cre-recombinase activity by
tamoxifen, is recombined, resulting in an inactive protein. The H19–
mouse strain was provided by S. Tilghman (Princeton University,
Princeton, New Jersey, USA) and carries a deletion in the imprinting
control region, ICR1, for Igf2, resulting in loss of imprinting. Maternal
inheritance of this deletion results in expression from the normally
silencedmaternal allele and biallelic expression of Igf2 [19]. Cohorts of
mutant and littermate controls were treated with 1 mg/40 g TM at
E11.5. The offspring were termed “Wt1-Igf2 mice” and were
monitored for tumor development as described further. The mice were
housed at an AAALAC-accredited small animal vivarium facility in
isosexual groups of 2 to 5, receiving regular chow andwater ad libitum;
the room was kept on a 12:12-h light/dark cycle and temperature was
maintained at 22 °C with relative humidity between 30 % and 70 %.
PET/CT Imaging Protocol
PET/CT imaging was performed using Inveon small animal PET/
CT instrument (Siemens, Knoxville, TN). The Wt1-Igf2 mice were
anesthetized with isoﬂurane (2 % in 98 % oxygen) and their
temperature kept at 38 °C with a heating pad using T/PUMP and T/
PADS (Gaymar Industries, Inc., Orchard Park, NY).
An iodine-based contrast agent Ioversol (678 mg/ml; Mallinck-
rodt, Hazelwood, MO) 200 μl was administered intraperitoneally
(i.p.) followed by 100 μl injected intravenously at 20 and 15 min
prior to imaging, respectively. The microCT imaging parameters
were: X-ray voltage of 80 kVp, anode current of 500 μA, and
exposure time of 300–350 milliseconds of each of the 360
rotational steps. CT images were reconstructed using Shepp–Logan
algorithm. The volume of individual tumor lesions was measured
by drawing regions of interest (ROI) outlining individual tumor
lesions on each CT slice, summing the areas of individual ROI
measured in all slices and multiplying by slice thickness to
calculate the lesion volume. Similar window and center settings
were used for determination of tumor boundaries to minimize errors
associated with volumetric analysis of images obtained at different
days of the study in different animals.
Static PET imaging studies were acquired for 15 min at 1, 2, and
3 h after i.v. administration of 18F-FDG (400 μCi in 100 μl of
saline) and reconstructed using two-dimensional ordered subsets
expectation maximization (2DOSEM) algorithm with four itera-
tions and 16 subsets. PET/CT image fusion and analysis were
performed using vendor software Inveon Research Workplace
version 3.0 (Siemens, Knoxville, TN). Tumor standardized uptake
value (SUV) for 18F-FDG was calculated by drawing ROI outlining
individual tumor lesions on CT images and transposing them to
corresponding PET images, as previously described [20].
MR Imaging Protocols
The Wt1-Igf2 mice were anesthetized with 1 % to 3 % isoﬂurane and
placed prone and head ﬁrst on the positioning sled. Electrocardiogra-
phy leads were positioned on the forepaws and tail, and respiratory
bellows were positioned over the abdomen. Imaging was done using
4.7-T small animal MRI scanner (Biospec, Bruker Biospin MRI,
Billerica, MA) with standard gradient (60 mm ID) volume RF recoil
(35 mm ID) conﬁgurations. Coronal and sagittal T1-weighted images
(TE/TR 8.5/620 ms) were acquired before and immediately after
injection via tail vein catheter of 0.4 ml/kg gadopentetate dimeglumine
(Magnevist; Berlex Laboratories, Inc., Montville NJ, USA); thereafter
T2-weighted images (TE/TR 60/300 ms) were acquired. Multi-slice
acquisition was performed with a ﬁeld-of-view of 50×37.5 mm and a
matrix of 256×192 points, slice thickness of 1 and 0.25 mm gap
between slices. All image analyses were performed using ImageJ
software (http://rsb.infp.nih.gov/ij).
Histopathology and Immunohistochemistry
Moribund mice were humanely sacriﬁced and after gross patho-
logical examination tumor tissues sampled, ﬁxed in 2 % parafor-
maldehyde and embedded in parafﬁn. Five-micrometer-thick tumor
tissue sections were obtained using the RM2255 microtome (Leica,
Germany), deparaﬁnized, and step-wise rehydrated in PBS. The
sections were blocked with either goat or hose serum for 2 h at
room temperature followed by incubation overnight at 4 °C with
primary rabbit monoclonal antibodies to Glut 1 (H-43) or fatty acid
synthase (C20G5; all from Santa Cruz, CA), followed by secondary
L.G. Flores II et al.: PET/CT Imaging of Transgenic Wilms Tumor Model 177
biotinylated goat anti-rabbit antibodies (BA-1000; Vector Labora-
tories, CA). Incubation with mouse monoclonal antibodies to Ki67
(MM1) was followed by biotinylated horse anti-mouse antibodies
(BA-2001; both from Vector Laboratories, CA). Goat antibodies to
CD34 (AF4117; R&D Systems, CA) and secondary rabbit anti-goat
biotinylated antibodies (BA-5000 Vector Laboratories, CA) were
used to detect microvasculature. Avidin-peroxidase and 3′3-
diaminobezidine were from Vectastain Elite kit (Vector Laborato-
ries, CA). Hematoxylin was used as a counterstain.
Monitoring Treatment Response
After detection of the developing tumors using 18F-FDG PET/CT
imaging, the Wt1-Igf2 mice (N06) were treated with a mitogen-
activated protein kinase (MEK) inhibitor U0126 (50 μmol/kg i.p. in
200 μl of 40 % DMSO in saline) every 4 days for 6 weeks [21].
18F-FDG PET/CT imaging was repeated at different days after
initiation of therapy with U0126. The percent change of initial
tumor volume and SUV changes were calculated, plotted over time,
and compared to non-treated animals.
Results
Optimization of CT and MRI Imaging Protocols
Initial CT imaging studies were conducted in normal
C57BL/6 mice (N06) to optimize the timing and volume
of i.v. injection of contrast agent. Pre-contrast CT images
resulted in a very poor soft tissue contrast (Fig. 1a). After
administration of i.v. contrast, increasing attenuation signal
from the renal cortico-medullary tissue was observed,
reaching a plateau after about 10 min, which is consistent
with the excretory phase of a nephrographic study [22].
However, the identiﬁcation of margins of organs adjacent to
kidneys using only the i.v. contrast was still not feasible.
Intraperitoneal co-administration of contrast prior to i.v.
contrast administration resulted in a signiﬁcant improvement
in delineation of margins of kidneys and other abdominal
organs (Fig. 1b). CT images obtained 30 min after combined
i.p. and i.v. dual-contrast administration provided a fairly
good delineation of renal tumor masses, which presented as
characteristically hypodense areas with clearly identiﬁable
borders with contrast-enhancing functional renal parenchy-
ma (Fig. 1c).
In Wt1-Igf2 mice, the renal tumor signal intensity on non-
enhanced T1 MR images was homogenous and only slightly
lower than that of the adjacent cortico-medullary renal
tissue, which did not provide sufﬁcient tumor-to-adjacent
kidney contrast (Fig. 1d). In T1-weighted contrast-enhanced
MR images, both tumor and adjacent kidney signal
intensities were similarly increased, which provided almost
no contrast between the tumor and peritumoral kidney tissue.
However, the T1 signal heterogeneity in the tumor tissue
was sometimes suggestive of tumor margins.
Overall, the best tumor-to-adjacent kidney contrast as
well as soft tissue contrast for other abdominal organs was
achieved using T2-weighted MRI (Fig. 1d). On T2-weighted
MR images, tumor tissue had an increased signal intensity,
which contrasted with relatively low T2 signal intensity of
the adjacent renal cortico-medullary tissue. A clearly
distinguishable tumor margin was usually observed on T2-
weighted MR images.
Optimization of 18F-FDG PET/CT Imaging
Protocol
In a preliminary PET study involving 4 Wt1-Igf2 mice,
delayed acquisition of PET images up to 3 h post 18F-FDG
administration resulted in a signiﬁcant clearance of 18F-FDG
from the kidneys and “unmasking” of areas or radioactivity
accumulation in the tumor tissue (Fig. 2). 18F-FDG PET/CT
imaging of Wt1-Igf2 mice using delayed image acquisition
protocol provided further characterization of tumor gluco-
lytic activity (Fig. 1e).
Immunohistochemical Characterization
of the Tumor Model
The level of Glut1 expression in renal tumors of Wt1-Igf2
mice was uniformly increased in the tumor cells (Fig. 3a),
which contributes to the mechanism of 18F-FDG accumula-
tion. The level of fatty acid synthase (FASN) expression in
tumor cells was only moderately increased in the majority of
tumor cells (Fig. 3b), which suggests that PET/CT imaging
with radiolabeled acetate or choline may not be effective, but
should also be explored. Proliferative activity in these
endogenous Wilms tumors was heterogeneous; higher
density of Ki67 labeling was typically observed in the
periphery of individual tumor lesions (Fig. 3c), which
suggests that PET/CT imaging with 18F-FLT and other
radiolabeled nucleoside analogues should be explored in the
future. Signiﬁcant neoangiogenesis was observed in tumors,
as evidenced by a dense network of CD34+ microvasculature
(Fig. 3d), which should contribute to contrast enhancement
on CT; however, CT contrast enhancement of these tumors
was signiﬁcantly less than in normal kidney parenchyma.
Long-Term Monitoring of Tumor Development
by PET/CT with 18F-FDG
Over the 8-month period, 46 Wt1-Igf2 mice and 8 littermate
control mice were studied. Amongst the Wt1-Igf2 mice, 48 %
was imaged once and 52 % was imaged at least three times per
month using 18F-FDG PET/CT with dual (i.p. and i.v.) contrast
enhanced CT (Fig. 4a). Renal tumors were identiﬁed in 54.3 %
of Wt1-Igf2 mice between post-natal 50–100 days. Renal
tumors were multifocal in 65.4 % of Wt1-Igf2 mice, while
34.6 % had a single detectable lesion only in one kidney. In
35.6 % of Wt1-Igf2 mice, tumors were localized in the right
kidney; in 24 %, in the left kidney, while 40.4 % of Wt1-Igf2
178 L.G. Flores II et al.: PET/CT Imaging of Transgenic Wilms Tumor Model
mice had bilateral kidney tumors. In Wt1-Igf2 mice, the
incidence of tumors was slightly higher in males (56 %) than
females (44 %). Invariably, the Wt1-Igf2 mice developed
hydronephrosis due to tumor-induced obstruction of urine
outﬂow from the renal pelvis or ureters. This caused a
signiﬁcant retention of 18F-FDG-derived radioactivity in the
kidney pelvis and parenchyma, which often confounded the
interpretation of PET/CT images (Fig. 4b). Extrarenal tumors
Fig. 1. In vivo MicroCT, MRI, and PET/CT in C57BL/6 and Wilms tumor model. Coronal CT images obtained a before and 1, 5,
10, and 30 min after i.v. injection of contrast in a normal C57BL/6 mouse; b at 10 and 30 min after i.v. and i.p. injection of
contrast in a normal C57BL/6 mouse; c obtained 1, 5, 10, and 30 min after i.p. and i.v. dual-contrast administration in a Wt1-
Igf2 mouse. d T1-weighted MR images before and after administration of an intravenous contrast (Gd-DTPA) and T2 image
obtained in the same Wt1-Igf2 mouse (shown in c) and e the corresponding image of 18F-FDG microPET/CT with dual contrast.
The CT images are shown in gray scale with the same window and center. Arrows point at the renal tumor mass.
Fig. 2. In vivo dual-contrast microCT and microPET/CT of a Wt1-Igf2 mouse with a renal (Wilms) tumor acquired at 60, 120,
and 180 min after i.v. administration of 18F-FDG. Arrows point at the renal tumor mass.
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were identiﬁed in 15.4 % of Wt1-Igf2 mice. The typical
localization of extrarenal intra-abdominal tumors was in the
lower abdominal peritoneal recesses, whichmay be due to local
dissemination of tumor cells developing implant metastases
(Fig. 4c, d).
A signiﬁcant impairment of renal excretory function of
the affected kidney(s) was observed in all animals at later
stages of tumor development, as evidenced by the absence of
contrast-enhancement of cortico-medullary renal tissue and
by a signiﬁcant decrease or absence of contrast material
outﬂow from the affected kidney. Further tumor growth
resulted in an almost complete destruction of kidney
anatomy and the formation of large heterogeneous tumor
masses with multiple urine-ﬁlled hemorrhagic cysts (Fig. 5).
To facilitate the comparison of tumor growth trends
between different animals, tumor volumes measured in
individual animals at different days after initial tumor
detection were normalized to the initial tumor volume
measured at the time of detection and expressed as % tumor
volume at the time of initial detection (which was set to
100 %). Also, to facilitate the comparison of 18F-FDG SUV
trends, the average tumor 18F-FDG SUVs was measured in
individual animals at different days after initial tumor
detection (Fig. 6a). Comparison of growth and glycolytic
activity of Wilms tumors in these transgenic mice over time
revealed that tumors exhibited a trend for increasing 18F-
FDG SUV during the ﬁrst 2 weeks after the initial detection
(Fig. 6a), when tumor volume was small (3–4 mm in
diameter). However, during the following 2 weeks of
monitoring, the average tumor 18F-FDG SUV signiﬁcantly
decreased, which was consistent with the development of
necrotic and cystic tumor regions and moderate-to-high
glycolytic activity persisting within viable tumors regions.
During the subsequent 4 weeks of monitoring, the average
tumor 18F-FDG SUV gradually increased, albeit not as
dramatically as during the initial phase of tumor growth.
Monitoring Therapy with a MEK Inhibitor
For the assessment of treatment response, we relied on
morphometry and 18F-FDG SUV of the most prominent
tumor lesions. Treatment with a MEK 1/2 inhibitor U0126
did not cause the inhibition of tumor growth, as compared to
untreated animals. However, after the ﬁrst three to four
doses (~2 weeks of treatment), a decrease in 18F-FDG SUV
was observed as compared to pre-treatment levels (pG0.05,
paired Student t test), which constitutes a metabolic
response. Six weeks later, despite continuing therapy, the
18F-FDG SUV increased again to previous levels (Fig. 6b).
Discussion
In this study, combined anatomical and molecular imaging
was utilized and optimized for characterization of a new
endogenous mouse model of Wilms tumor. In this tumor
model, somatic inactivation of the Wt1 gene occurs in the
context of bi-allelic over-expression of the Igf2 gene in a
small subset of differentiating metanephric mesenchymal
cells. This is achieved by a conditional ablation of the Wt1
gene via dose-dependent, tamoxifen-inducible, Cre-mediated
recombination of the Wt1ﬂ allele, which results in a Wt1Δ
Fig. 3. Immunohistochemical characterization of Wilms tumor tissue for expression of a Glut 1, b fatty acid synthetase (FASN),
c Ki67 (proliferating cells), and d CD34+ microvasculature.
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allele encoding a truncated mutant WT1 protein that is
functionally indistinguishable from the Wt1– allele [18, 23].
Such an approach allows for normal embryonal development
of functional kidneys, which warrants postnatally viable
offspring and mimics the alterations observed in human
tumors. Previous studies demonstrated that Wt1-Igf2 tumors
recapitulate the histology and signature of gene expression
of human Wilms tumors [18]. Because combined alterations
in IGF2 and WT1 genes causes dysregulation of ERK
signaling pathway, similar to that observed in human
Fig. 4. Repetitive microPET/CT with 18F-FDG and dual-enhanced CT of bilateral renal tumors in Wt1-Igf2 mice. a CT images
obtained at 41 days demonstrate a significant deformation of renal pelvis and collicular architecture of both kidneys due to
presence of multi-focal tumor lesions with increased glycolytic activity on PET. PET/CT Images of the same animal obtained at
76 and 106 days demonstrate a significant increase in size of individual tumor lesions, coalescence of tumor lesions into larger
tumor masses with apparent decrease in glycolytic activity in most tumors. b In some animals, PET/CT images revealed a
significant decrease in renal clearance of 18F-FDG, which manifested by high persistent radioactivity in the obstructed kidney. c
PET/CT images of a Wt1-Igf2 mouse with extrarenal glycolytically active metastatic tumor lesion growing intra-abdominally on
the right side at 41 days; this tumor lesion has grown through the abdominal wall into the subcutaneous space and remained
glycolytically active 20 days later. d PET/CT images of another Wt1-Igf2 mouse with glycolytically active extrarenal metastasis
growing intra-abdominally on the left side at 51 days, and invading the abdominal wall muscles 10 days later.
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tumors, the current model can be used for the assessment of
therapeutic efﬁcacy of drugs targeting IGF and ERK
signaling pathways.
However, the variability of onset and dynamics of Wilms
tumor development in these Wt1-Igf2 mice dictates the need
for highly sensitive non-invasive imaging, to enable early
detection of tumor lesions in kidneys and for longitudinal
monitoring of their progression or regression for the
assessment of novel therapeutic strategies targeting IGF
and ERK signaling pathways. Detection of orthotopic and
endogenous Wilms tumors using contrast-enhanced CT or
T1-weighted MRI is challenging because kidneys are
involved in clearance of CT and MRI contrast agents.
Delineation of renal tumor masses on contrast-enhanced CT
and MR images is based on a negative contrast, which is due
to higher perfusion and excretion of contrast agent by the
normal kidney tissue, as compared to tumor tissue lacking
the excretory function [24]. Therefore, renal tumors are
detectable more reliably using T2-weighted MRI, which is
due to signiﬁcantly higher signal intensity of tumor tissue, as
compared to normal kidney tissue [25]. The results of
current imaging studies in Wt1-Igf2 mice have conﬁrmed
the higher accuracy of T2-weighted MRI for early detection,
delineation of margins, and for assessment of structural
heterogeneity of Wilms tumors, as compared to T1-weghted
MRI and CT with or without i.v. contrast enhancement.
Fig. 5. MicroPET with double enhanced CT of Wt1-Igf2 mice with bilateral renal tumors obtained at different times during
development. a In one Wt1-Igf2 mouse obstractive hydronephrosis was detectable in the right kidney, which manifested by
retention of 18F-FDG and CT contrast in the renal pelvis; in the left kidney, the developing tumor has gradually destroyed the
whole kidney and retained a glucolytically active core. b In another Wt1-Igf2 mouse a large tumor that completely destroyed the
right kidney had multiple hemorrhagic cysts (evident at gross pathologic examination), which explains the relatively lower
average glucolytic activity.
Fig. 6. Quantification of a tumor growth expressed as % initial tumor volume and b 18F-FDG SUV over time (days post initial
initiation of therapy) in Wt1-Igf2 mice treated with MEK inhibitor UO126 (open squares) and control littermate mice receiving
saline (filled circles).
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Previously, Johnson et al. [26] reported that administration
of intraperitoneal contrast results in an opaciﬁcation of
intraperitoneal ﬂuid and a signiﬁcant improvement of visuali-
zation of boundaries of different abdominal organs. The current
study also demonstrated the efﬁcacy of dual contrast-enhanced
CT (using co-administration i.v. and i.p. contrast) for detection
andmonitoring of renal tumors inWt1-Igf2mice. Dual-contrast
CT provided a better delineation of tumor boundaries in
relation to neighboring organs, especially in advanced Wilms
tumors causing signiﬁcant displacement of abdominal organs.
Furthermore, as an alternative to T2-weighted MRI, dual-
contrast enhanced CT was implemented as part of a PET/CT
imaging protocol, which simpliﬁed handling of the experimen-
tal animals between different imaging modalities and mini-
mized errors of inter-modality co-registration of anatomical and
functional (molecular) images.
Small animal PET and PET/CT imaging with different
radiotracers have been widely used for detection, character-
ization of metabolic and signaling abnormalities, and for
monitoring of various therapeutic approaches in transgenic
mouse tumor models [27–33]. In particular, PET imaging
with 2′-[18F]-ﬂuoro-2′-deoxy-D-glucose (18F-FDG) has been
extensively utilized for detection of tumors with increased
glycolytic activity, which results from de-regulated onco-
genic signaling [34], which causes the “Warburg” effect
[35]. Application of 18F-FDG PET for early detection and
characterization of kidney tumors in mice is challenging, due
to predominantly renal clearance of 18F-FDG from the
circulation, which generates high level of normal kidney
radioactivity and obscures small renal tumor masses.
Therefore, in orthotopic renal carcinoma models 18F-FDG
PET has been used mainly to detect distal metastatic lesions
[36]. However, PET/CT imaging provides signiﬁcantly more
accurate diagnostic information, as compared to CT or PET
imaging alone. In clinical setting, PET/CT has been useful in
identifying the most metabolically active portions of tumors
for targeting of biopsies, staging, monitoring responses to
chemotherapy, and for disease surveillance [37, 38]. Also,
previous clinical studies demonstrated that administration of
CT contrast agent does not signiﬁcantly impair the quality of
18F-FDG PET images [39].
The current study demonstrated the applicability of 18F-
FDG PET/CT for detection of early stage developing WT
lesions as well as limitations for monitoring their growth in
this endogenous mouse model of Wilms tumor. The
rationale for using PET/CT imaging with 18F-FDG in this
tumor model was based on the overexpression of Igf2 and
deletion of Wt1. Mutational inactivation of WT1 tumor
suppressor also leads to activation of the IGF-1R signaling
and its downstream targets such as Grb2 which signals
through Ras, Raf, and ultimately mitogen-activated protein
kinase (MAPK), which is involved in cellular events such as
growth, differentiation, and stress response [40]. Growth
factors such as IGF1 and IGF2 drive HIF-1α through MEK1
and MEK2 signaling, that inﬂuences tumor glucolytic
activity [41]. Furthermore, MAPK signaling facilitates
malignant transformation, drives growth and progression of
tumor and enhances its ability to invade and metastasize [42,
43]. This explains, at least in part, why several Wt1-Igf2
mice also developed not only renal tumors, but also
extrarenal metastatic tumor lesions. These metastatic tumors
may have initially developed by peritoneal dissemination of
tumor cells invading through the renal capsule or released as
the result of rupture of subcapsular cystic tumor lesions.
However, at later stages of growth, these metastatic lesions
have grown through the abdominal muscles and often
extended into the subcutaneous space, which demonstrates
their invasive phenotype.
The upregulation of Igf2 in this Wilms tumor model
causes increased signaling through the IGF-IR via pIRS1
and pERK1/2, which drives the proliferation of these
abnormal cells [18]. It is noteworthy, that a signiﬁcant
fraction of human WTs also exhibits increased pIRS1 and
pERK1/2 [18]. ERK is a downstream component of a
signaling cascade that is activated by the Raf serine/
threonine kinases. Raf activates the MAPK/ERK kinase
(MEK)1/2 dual-speciﬁcity protein kinases, which then
activate ERK1/2 [44]. Therefore, in this study we used
U0126, a highly selective inhibitor of MEK1 and MEK2
[21], to assess its therapeutic efﬁcacy in this Wilms tumor
model and to investigate whether the U0126 would induce
changes in tumor glycolytic activity that can be used as a
potential pharmacodynamic biomarker. Using repetitive 18F-
FDG PET/CT with dual contrast CT, we observed only
transient inhibition of glucolytic activity during the ﬁrst
week of therapy with U0126 at doses that have been proven
effective in therapy of other tumor types [21]. However, no
signiﬁcant differences in the dynamics of tumor growth were
observed between U0126 treated and untreated animals. The
lack of therapeutic efﬁcacy of U0126 in this Wilms tumor
model and only a transient decrease of glucolytic activity
could be explained, at least in part, by continuing IGF2-
induced signaling from IGF1R through the PI3K-AKT-
mTOR pathway [45], bypassing the block in MAPK
signaling. Although, our previous studies in this Wilms
tumor model demonstrated no signiﬁcant upregulation of
Akt phosphorylation [18], it is possible that persistent PI3K-
AKT-mTOR signaling may compensate for the inhibited
MAPK signaling during therapy with a MEK inhibitor. The
current study demonstrated that genetic and signaling
aberrations in this Wilms tumor model ultimately lead to
upregulation of glucose transporter (Glut1) expression and
hexokinase activity, which explains increased 18F-FDG
accumulation and enables the detection of early stage tumor
lesions. However, at later stages of tumor development, the
observed variability of 18F-FDG accumulation in tumors
reﬂects the heterogeneity of GLUT1 expression in a
polycystic-hemorrhagic tumor tissue. Our ﬁndings are in
agreement with previous studies in Wilms tumor patients,
demonstrating that 18F-FDG PET was effective in detection
of both primary tumors, as well as residual disease after
therapy and disease extent at relapse [46, 47].
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Because this Wilms tumor model is characterized with a
moderately increased tumor Ki67 labeling index, PET/CT
imaging with 18F-FLT may be suitable for monitoring tumor
proliferative activity. Also, the level of FASN expression in
this model of Wilms tumor was only moderately increased,
which suggests that PET/CT imaging with radiolabeled acetate
and choline may not be suitable for detection and therapy
monitoring in this Wilms tumor model. To date, there are no
published reports on the efﬁcacy of radiolabeled acetate and
choline for PET/CT imaging of Wilms tumors in human
subjects. As PET/MRI hybrid imaging systems became more
widely available for pre-clinical and clinical applications [48,
49], T2-weighted MRI and PET using metabolic radiotracers
such as 18F-FDG or alternative radiotracers with signiﬁcantly
less renal clearance (i.e., 11C-acetate) should further be
explored for detection and longitudinal monitoring of treatment
responses of Wilms tumors.
In summary, renal tumors developing in Wt1-Igf2 mice
carry the same alterations that occur in human tumors, thus
recapitulating the process of development and progression of
Wilms tumor in human patients and providing a highly
relevant model for testing new molecular targeted therapies.
Renal tumors in Wt1-Igf2 mice accumulate 18F-FDG due to
upregulation of Glut-1 and hexokinase activity. The opti-
mized PET/CT imaging with dual-contrast CT and delayed
acquisition of PET images at 3 h post 18F-FDG administra-
tion provides a sensitive and reliable method for detecting
early kidney tumors in this Wilms tumor model. Therapy
with MEK inhibitor U0126 produces only a transient
inhibition of tumor glycolytic activity but does not inhibit
tumor growth, which is most likely due to continuing IGF2-
induced signaling from IGF1R through the PI3K-AKT-
mTOR pathway.
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